Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging

[1]  M. Gleave,et al.  High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  K. Rahbar,et al.  Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management , 2021, Cancers.

[3]  Hua Wu,et al.  Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  K. Rahbar,et al.  Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy , 2020, Theranostics.

[5]  Liang Zhao,et al.  68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer. , 2020, Clinical nuclear medicine.

[6]  K. Rahbar,et al.  Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy , 2020, The Journal of Nuclear Medicine.

[7]  U. Haberkorn,et al.  Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[9]  E. Jones,et al.  68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. , 2019, Radiology. Imaging cancer.

[10]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[11]  D. Murphy,et al.  Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. , 2019, European urology oncology.

[12]  E. Song,et al.  Turning foes to friends: targeting cancer-associated fibroblasts , 2018, Nature Reviews Drug Discovery.

[13]  D. Jäger,et al.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts , 2018, The Journal of Nuclear Medicine.

[14]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[15]  Frederik L. Giesel,et al.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers , 2018, The Journal of Nuclear Medicine.

[16]  K. Rahbar,et al.  Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  E. Puré,et al.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics , 2018, Oncogene.

[18]  K. Rahbar,et al.  18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  Qian Zhang,et al.  Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer. , 2017, Oncology letters.

[20]  P. Claus,et al.  Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction , 2017, Scientific Reports.

[21]  P. Humphrey,et al.  Histopathology of Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[22]  U. Haberkorn,et al.  Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging , 2017, The Journal of Nuclear Medicine.

[23]  B. Hadaschik,et al.  F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  W. Jiang,et al.  Promotion of Cellular Growth and Motility Is Independent of Enzymatic Activity of Fibroblast Activation Protein-α. , 2016, Cancer genomics & proteomics.

[25]  O. De Wever,et al.  Fibroblast activation protein‐α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations , 2016, Molecular oncology.

[26]  Dehai Che,et al.  Fibroblast Activation Protein Overexpression and Clinical Implications in Solid Tumors: A Meta-Analysis , 2015, PloS one.

[27]  Ji Xu,et al.  Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1 , 2014, Cancer science.

[28]  Bo Zhou,et al.  MicroRNA‐106b in cancer‐associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN , 2014, FEBS letters.

[29]  H. Janssen,et al.  Increased N‐terminal cleavage of alpha‐2‐antiplasmin in patients with liver cirrhosis , 2013, Journal of thrombosis and haemostasis : JTH.

[30]  E. Puré,et al.  Fibroblast activation protein in remodeling tissues. , 2012, Current molecular medicine.

[31]  J. Isaacs,et al.  Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy , 2012, Molecular Cancer Therapeutics.

[32]  Ricardo Garcia,et al.  Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis , 2011, Cell.

[33]  Y. Toiyama,et al.  Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. , 2011, International journal of oncology.

[34]  Deborah Caine,et al.  Back to the Basics , 2021, Interceram - International Ceramic Review.

[35]  U. Müller-Ladner,et al.  Microarrays demystified. , 2004, Environmental health perspectives.

[36]  K. Gebo.  Implications for Patient Management , 2006 .

[37]  D. Gotley,et al.  Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis , 2003, Thrombosis and Haemostasis.

[38]  A. Schnapp,et al.  Expression of the fibroblast activation protein during mouse embryo development. , 2001, The International journal of developmental biology.

[39]  K. Rahbar,et al.  Diagnostic performance of 18 F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer , 2022 .